---
layout: default
title: Angiotensin Ii Acetate
parent: Pelkkä mallin ennuste (L5)
nav_order: 32
evidence_level: L5
indication_count: 0
---

# Angiotensin Ii Acetate
{: .fs-9 }

Näytön taso: **L5** | Ennustetut käyttöaiheet: **0** kpl
{: .fs-6 .fw-300 }

---

## Sisällysluettelo
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Farmaseutin arviointiraportti

</div>

# Angiotensin II Acetate: Drug Repurposing Evaluation Report

## One-Sentence Summary

Angiotensin II Acetate is a synthetic vasopressor peptide, primarily used in clinical practice to manage distributive (vasodilatory) shock. The TxGNN model did not return any predicted new indications for this drug in this evidence pack, and no Taiwan market authorizations were identified. A complete repurposing evaluation **cannot be generated** at this stage due to critical data gaps across prediction, safety, and regulatory dimensions.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Distributive shock / vasodilatory shock (vasopressor support) |
| Predicted New Indication | None — TxGNN prediction output not available |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 — No model prediction output generated |
| Taiwan Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Safety Considerations

Please refer to the package insert for safety information.

> Note: The TFDA package insert query returned 1 result (see query log entry #4), but the structured safety fields — including key warnings, contraindications, and drug interactions — were not populated in this evidence pack. The package insert data requires manual extraction before safety screening can proceed.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN model produced no predicted indications for Angiotensin II Acetate, and critical drug-level data (MOA, safety warnings, contraindications) remain unresolved data gaps. Without a prediction output, there is no repurposing candidate to evaluate.

**To proceed, the following is needed:**

- **TxGNN prediction output**: Re-run the TxGNN pipeline with the correct DrugBank entity ID for Angiotensin II Acetate to obtain ranked indication predictions and confidence scores
- **DrugBank ID**: The DrugBank query returned 1 result but `drugbank_id` was not captured; confirm the mapped ID (likely DB09280 — Angiotensin II) and populate the evidence pack
- **MOA data**: Extract mechanism of action from DrugBank (AT1 receptor agonist → vasoconstriction) to enable mechanistic plausibility analysis
- **Safety data**: Parse the TFDA package insert PDF retrieved in query log entry #4 to populate key warnings and contraindications
- **Original indications**: Confirm the approved indication(s) from the package insert to complete the regulatory profile
## Vastuuvapauslauseke

Tämä sisältö on tarkoitettu ainoastaan tutkimuskäyttöön eikä se ole lääketieteellistä neuvontaa.
Kliininen validointi vaaditaan ennen kliinistä käyttöä.

---

